Frontiers in Genetics (Oct 2024)

Identification of novel 3D-genome altering and complex structural variants underlying retinitis pigmentosa type 17 through a multistep and high-throughput approach

  • Suzanne E. de Bruijn,
  • Daan M. Panneman,
  • Nicole Weisschuh,
  • Elizabeth L. Cadena,
  • Erica G. M. Boonen,
  • Lara K. Holtes,
  • Galuh D. N. Astuti,
  • Frans P. M. Cremers,
  • Nico Leijsten,
  • Jordi Corominas,
  • Christian Gilissen,
  • Anna Skowronska,
  • Jessica Woodley,
  • Andrew D. Beggs,
  • Vasileios Toulis,
  • Di Chen,
  • Michael E. Cheetham,
  • Alison J. Hardcastle,
  • Terri L. McLaren,
  • Terri L. McLaren,
  • Tina M. Lamey,
  • Jennifer A. Thompson,
  • Fred K. Chen,
  • Fred K. Chen,
  • Fred K. Chen,
  • John N. de Roach,
  • John N. de Roach,
  • Isabella R. Urwin,
  • Lori S. Sullivan,
  • Susanne Roosing

DOI
https://doi.org/10.3389/fgene.2024.1469686
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionAutosomal dominant retinitis pigmentosa type 17 (adRP, type RP17) is caused by complex structural variants (SVs) affecting a locus on chromosome 17 (chr17q22). The SVs disrupt the 3D regulatory landscape by altering the topologically associating domain (TAD) structure of the locus, creating novel TAD structures (neo-TADs) and ectopic enhancer-gene contacts. Currently, screening for RP17-associated SVs is not included in routine diagnostics given the complexity of the variants and a lack of cost-effective detection methods. The aim of this study was to accurately detect novel RP17-SVs by establishing a systematic and efficient workflow.MethodsGenetically unexplained probands diagnosed with adRP (n = 509) from an international cohort were screened using a smMIPs or genomic qPCR-based approach tailored for the RP17 locus. Suspected copy number changes were validated using high-density SNP-array genotyping, and SV breakpoint characterization was performed by mutation-specific breakpoint PCR, genome sequencing and, if required, optical genome mapping. In silico modeling of novel SVs was performed to predict the formation of neo-TADs and whether ectopic contacts between the retinal enhancers and the GDPD1-promoter could be formed.ResultsUsing this workflow, potential RP17-SVs were detected in eight probands of which seven were confirmed. Two novel SVs were identified that are predicted to cause TAD rearrangement and retinal enhancer-GDPD1 contact, one from Germany (DE-SV9) and three with the same SV from the United States (US-SV10). Previously reported RP17-SVs were also identified in three Australian probands, one with UK-SV2 and two with SA-SV3.DiscussionIn summary, we describe a validated multi-step pipeline for reliable and efficient RP17-SV discovery and expand the range of disease-associated SVs. Based on these data, RP17-SVs can be considered a frequent cause of adRP which warrants the inclusion of RP17-screening as a standard diagnostic test for this disease.

Keywords